search
Back to results

Two Chemotherapy Regimens Plus or Minus Bevacizumab (BETTER2)

Primary Purpose

Pancreatic Cancer

Status
Recruiting
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
LV5FU2
Streptozocin
Capecitabine
Temozolomide
Bevacizumab
Sponsored by
Gustave Roussy, Cancer Campus, Grand Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pancreatic Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Well differentiated pancreatic neuroendocrine tumor grade 1 (NET G1) or grade 2 (NET G2) or grade 3 (NET G3)
  2. Indication for chemotherapy for locally advanced or metastatic disease with proven progression (at least 20% increase of tumor size on a maximum 12 months period of follow-up) or other indication of chemotherapy following the National Thesaurus of GI Cancerology (Appendix 6) (liver involvement > 50%, symptoms related to the tumour or its metastases, Ki67>10%) (Appendix 6)
  3. Patient with at least one measurable target tumor by RECIST 1.1 that thas never been irradiated
  4. Patient with a life expectancy greater than 3 months
  5. Men or women with performance status (ECOG) ≤ 2
  6. Age ≥ 18 years
  7. Adequate hematological function: neutrophil count (ANC) ≥ 1,5x109/L, platelets >/= 75x109/L, hemoglobin >/= 10g/dl (blood transfusions are accepted to reach this level).
  8. Adequate liver function: serum bilirubin </= 3 x upper limit of normal (ULN); aminotransferases and alkaline phosphatase levels </= 2.5 ULN (</= 5 ULN if liver metastases), TP > 50%
  9. Proteinuria ≤ 1g/24 h, blood creatinine less than 120 μmol/L and creatinin clearance ≥ 60 ml/min as calculated by Cockroft-Gault formula Note: a negative dipstick urine analysis is sufficient.
  10. Absence of active bleeding, coagulopathy or pathologic condition that would confer a high risk of bleeding
  11. Prior treatment with somatostatin analogues, everolimus or sunitinib is allowed
  12. Negative serum pregnancy test ≤ 72 hours before randomization (for women of childbearing potential only). Sexually active women of childbearing potential must agree to use a highly effective method of contraception or to abstain from sexual activity during the study and for at least 6 months after the last study treatment administration. Sexually active males patients must agree to use condom during the study and for at least 6 months after the last study treatment administration. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception.
  13. Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
  14. Patient affiliated to a social security regimen or beneficiary of such regimen

Exclusion Criteria:

  1. Disease accessible to resection or percutaneous method of destruction
  2. Any known allergy or contraindication to the treatments used in the trial, 2.1 Patients with a complete DPD deficiency; defined as an uracil concentration ≥150ng/ml Note: patients with a suspicion of partial DPD deficiency, defined as a uracil concentration ≥ 16 ng/ml and < 150 ng/ml, will receive an adapted 1st cycle dose, according to a clinic-biological discussion. The dose can be then readapted for the second cycle according to the tolerability of the treatment during the 1st cycle.
  3. Patient previously treated with chemotherapy for the neuroendocrine tumour
  4. Patient have received any other antitumor therapy: chemotherapy, immunotherapy
  5. Other serious diseases such as respiratory failure or congestive heart failure, angina pectoris not medically controlled. History of myocardial infarction, within 6 months prior to study entry, uncontrolled hypertension and arrhythmias, concomitant severe infection or uncontrolled diabetes mellitus.
  6. Subjects with a history of chronic or acute hepatitis C or B infection.
  7. Surgery during the 5 weeks preceding the randomization
  8. History of cancer (except basal cell skin or carcinoma in situ carcinoma of the cervix) within 5 years prior to entry into the trial. But patients with cancers that have been treated more than 5 years ago and are considered as cured are eligible.
  9. Neurological or psychiatric pathology that may interfere with adherence to treatment
  10. Patients have received yellow fever vaccine within 30 days prior to the first dose of trial treatment.
  11. Patient with pernicious anaemia and other megaloblastic anaemias secondary to the lack of Vitamin B12
  12. Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies
  13. Hypersensitivity to study drugs or any of its excipients
  14. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
  15. Pregnant or breast feeding women

Sites / Locations

  • Centre Antoine LacassagneRecruiting
  • CHU de CaenRecruiting
  • CHU de DijonRecruiting
  • Hôpital Haut-LévêqueRecruiting
  • IUCT - Hôpital RangueilRecruiting
  • Hôpital BeaujonRecruiting
  • ICM Val d'Aurelle
  • Hôpital Trousseau CHU Tours
  • Institut de Cancérologie de l'Ouest site René GauducheauRecruiting
  • CHR d'Orléans
  • CHU Angers
  • Hôpital Haut-LévêqueRecruiting
  • Institut de Cancérologie de LorraineRecruiting
  • Hôpital Edouard HerriotRecruiting
  • Gustave RoussyRecruiting
  • Hôpital Croix St SimonRecruiting
  • Hôpital Saint-Antoine
  • Hôpital CochinRecruiting
  • Hôpital Européen Georges Pompidou
  • Centre Eugène MarquisRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

LV5FU2 + streptozotocin

Capecitabine + temozolomide

LV5FU2 + streptozotocin + Bevacizumab

Capecitabine + temozolomide + Bevacizumab

Arm Description

Outcomes

Primary Outcome Measures

Progression Free Survival (PFS) rate

Secondary Outcome Measures

Toxicity (NCI-CTCAE 4.0)

Full Information

First Posted
November 20, 2017
Last Updated
May 16, 2023
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Collaborators
National Cancer Institute, France
search

1. Study Identification

Unique Protocol Identification Number
NCT03351296
Brief Title
Two Chemotherapy Regimens Plus or Minus Bevacizumab
Acronym
BETTER2
Official Title
Randomized Phase 2 Trial Of Two Chemotherapy Regimens Plus Or Minus Bevacizumab In Patients With Well Differentiated Pancreatic Neuroendocrine Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 26, 2018 (Actual)
Primary Completion Date
December 2028 (Anticipated)
Study Completion Date
December 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Collaborators
National Cancer Institute, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Compare the effect of capecitabine (cape) + temozolomide (temo) and of 5FU + streptozotocin (strepto) given with a new schedule (LV5FU2 + strepto), two of the most used chemotherapy regimens in the treatment of well differentiated pancreatic neuroendocrine tumors alone or in combination with bevacizumab (beva) on progression-free survival (PFS) and compare the chemotherapy regimens alone or with beva (two by two design) on the same criteria.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Comparative phase II trial with two randomizations
Masking
None (Open Label)
Allocation
Randomized
Enrollment
140 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LV5FU2 + streptozotocin
Arm Type
Experimental
Arm Title
Capecitabine + temozolomide
Arm Type
Experimental
Arm Title
LV5FU2 + streptozotocin + Bevacizumab
Arm Type
Experimental
Arm Title
Capecitabine + temozolomide + Bevacizumab
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
LV5FU2
Intervention Description
LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)
Intervention Type
Drug
Intervention Name(s)
Streptozocin
Intervention Description
streptozotocin 800 mg/m² day 1 every 14 days
Intervention Type
Drug
Intervention Name(s)
Capecitabine
Intervention Description
Capecitabine 750 mg/m² twice daily, days 1-14
Intervention Type
Drug
Intervention Name(s)
Temozolomide
Intervention Description
temozolomide 200 mg/m² once daily, days 10-14, every 28 days
Intervention Type
Drug
Intervention Name(s)
Bevacizumab
Intervention Description
bevacizumab 5 mg/kg every 14 days
Primary Outcome Measure Information:
Title
Progression Free Survival (PFS) rate
Time Frame
Until disease progression or unacceptable toxicity (median 24 months)
Secondary Outcome Measure Information:
Title
Toxicity (NCI-CTCAE 4.0)
Time Frame
Until disease progression or unacceptable toxicity

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Well differentiated pancreatic neuroendocrine tumor grade 1 (NET G1), grade 2 (NET G2) or grade 3 (NET G3)* *Grade 3 tumor must be confirmed by a pathologist of the TENpath network. Indication for chemotherapy for locally advanced or metastatic disease with proven progression (at least 20% increase of tumor size on a maximum of 12 months period of follow-up) or other indication of chemotherapy following the National Thesaurus of GI Cancerology (Appendix 6) (liver involvement > 50%, symptoms related to the tumour or its metastases, Ki67>10%) Patient with at least one measurable target tumor by RECIST 1.1 and that has never been irradiated Patient with a life expectancy greater than 3 months Men or women with performance status (ECOG) ≤ 2 (Appendix 3) Age ≥ 18 years Adequate hematological function: neutrophil count (ANC) ≥ 1.5x109/L, platelets greater than 75x109/L, hemoglobin greater than 10g/dl (blood transfusions are accepted to reach this level). Adequate liver function: serum bilirubin lower than 3 x upper limit of normal (ULN); aminotransferases and alkaline phosphatase levels lower than 2.5 ULN (lower than 5 ULN if liver metastases), TP greater than 50 % Proteinuria lower than 1g/24h, blood creatinine less than 120 μmol/L and creatinin clearance ≥ 60 ml/min as calculated by Cockroft-Gault formula Note: a negative dipstick urine analysis is sufficient. Absence of active bleeding, coagulopathy or pathologic condition that would confer a high risk of bleeding Prior treatment with somatostatin analogues, everolimus or sunitinib is allowed Negative serum pregnancy test ≤ 72 hours before randomization (for women of childbearing potential only). Sexually active women of childbearing potential must agree to use a highly effective method of contraception or to abstain from sexual activity during the study and for at least 6 months after the last study treatment administration. Sexually active males patients must agree to use condom during the study and for at least 6 months after the last study treatment administration. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception. Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol. Patient affiliated to a social security regimen or beneficiary of such regimen Non inclusion criteria : Disease accessible to resection or percutaneous method of destruction Any known allergy or contraindication to the treatments used in the trial Patients with a complete DPD deficiency; defined as an uracil concentration ≥150ng/ml Note: patients with a suspicion of partial DPD deficiency, defined as a uracil concentration ≥ 16 ng/ml and < 150 ng/ml, will receive an adapted 1st cycle dose, according to a clinic-biological discussion. The dose can be then readapted for the second cycle according to the tolerability of the treatment during the 1st cycle. Patient previously treated with chemotherapy for the neuroendocrine tumour Patient have received any other antitumor therapy: chemotherapy, immunotherapy Other serious diseases such as respiratory failure or congestive heart failure, angina pectoris not medically controlled; history of myocardial infarction within 6 months prior to study entry, uncontrolled hypertension and arrhythmias, concomitant severe infection or uncontrolled diabetes mellitus Subjects with a history of chronic or acute hepatitis C or B infection. Surgery during the 5 weeks preceding the randomization History of cancer (except basal cell skin or carcinoma in situ carcinoma of the cervix) within 5 years prior to entry into the trial. But patients with cancers that have been treated more than 5 years ago and are considered as cured are eligible. Neurological or psychiatric pathology that may interfere with adherence to treatment Patients have received yellow fever vaccine within 30 days prior to the first dose of trial treatment. Patient with pernicious anaemia and other megaloblastic anaemias secondary to the lack of Vitamin B12 Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies Hypersensitivity to study drugs or any of its excipients Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent Pregnant or breast feeding women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michel Ducreux, MD, PhD
Phone
+33 (0)1 42 11 60 17
Email
michel.ducreux@gustaveroussy.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Catherine RICHON
Phone
+33 (0)1 42 11 23 44
Email
catherine.richon@gustaveroussy.fr
Facility Information:
Facility Name
Centre Antoine Lacassagne
City
Nice
State/Province
Alpes-Maritimes
ZIP/Postal Code
06189
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ludovic EVESQUE, MD
Email
ludovic.evesque@nice.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Feryel SAHMIM
Email
Feryel.SAHMIM@nice.unicancer.fr
Facility Name
CHU de Caen
City
Caen
State/Province
Calvados
ZIP/Postal Code
14033
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karine BOUHIER ép. LEPORRIER, MD
Email
bouhierleporrier-k@chu-caen.fr
First Name & Middle Initial & Last Name & Degree
Esther LEBRETON
Email
lebreton-e@chu-caen.fr
Facility Name
CHU de Dijon
City
Dijon
State/Province
Côte d'Or
ZIP/Postal Code
21000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Côme LEPAGE, MD
Email
come.lepage@u-bourgogne.fr
First Name & Middle Initial & Last Name & Degree
Janice MIENS
Email
janice.miens@chu-dijon.fr
Facility Name
Hôpital Haut-Lévêque
City
Pessac
State/Province
Gironde
ZIP/Postal Code
33600
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Denis SMITH, MD
Email
denis.smith@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Ana MUSTEL
Email
ana.mustel@chu-bordeaux.fr
Facility Name
IUCT - Hôpital Rangueil
City
Toulouse
State/Province
Haute-Garonne
ZIP/Postal Code
31400
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rosine GUIMBAUD, MD
Email
guimbaud.r@chu-toulouse.fr
First Name & Middle Initial & Last Name & Degree
Caroline GREGOIRE
Email
gregoire.c@chu-toulouse.fr
Facility Name
Hôpital Beaujon
City
Clichy
State/Province
Hauts-de-Seine
ZIP/Postal Code
92110
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Olivia HENTIC, MD
Email
olivia.hentic@aphp.fr
First Name & Middle Initial & Last Name & Degree
Maher AKEZ
Email
maher.akez-ext@aphp.fr
Facility Name
ICM Val d'Aurelle
City
Montpellier
State/Province
Hérault
ZIP/Postal Code
34298
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric ASSENAT, MD
Email
Eric.Assenat@icm.unicancer.fr
First Name & Middle Initial & Last Name & Degree
JOUET JOUET
Email
Noelle.Jouet@icm.unicancer.fr
Facility Name
Hôpital Trousseau CHU Tours
City
Chambray-lès-Tours
State/Province
Indre-et-Loire
ZIP/Postal Code
37170
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thierry LECOMTE, MD
Email
thierry.lecomte@univ-tours.fr
First Name & Middle Initial & Last Name & Degree
Elodie ROY
Email
elodie.roy@chu-tours.fr
Facility Name
Institut de Cancérologie de l'Ouest site René Gauducheau
City
Saint-Herblain
State/Province
Loire-Atlantique
ZIP/Postal Code
44800
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hélène SENELLART, MD
Email
Helene.Senellart@ico.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Mathilde PRUNIER
Email
Mathilde.prunier@ico.unicancer.fr
Facility Name
CHR d'Orléans
City
Orléans
State/Province
Loiret
ZIP/Postal Code
45067
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Louis LEGOUX, MD
Email
jean-louis.legoux@chr-orleans.fr
First Name & Middle Initial & Last Name & Degree
Brahim OUAHRANI
Email
brahim.ouahrani@chr-orleans.fr
Facility Name
CHU Angers
City
Angers
State/Province
Maine-et-Loire
ZIP/Postal Code
49100
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guillaume ROQUIN, MD
Email
guroquin@chu-angers.fr
First Name & Middle Initial & Last Name & Degree
Nathanaëlle CORNET
Email
NaTrichereau@chu-angers.fr
Facility Name
Hôpital Haut-Lévêque
City
Reims
State/Province
Marne
ZIP/Postal Code
51092
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guillaume CADIOT, MD
Email
gcadiot@chu-reims.fr
First Name & Middle Initial & Last Name & Degree
Anne GALLAIRE
Email
agallaire-lukaszewiez@chu-reims.fr
Facility Name
Institut de Cancérologie de Lorraine
City
Vandœuvre-lès-Nancy
State/Province
Meurthe-et-Moselle
ZIP/Postal Code
54519
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aurélien LAMBERT, MD
Email
a.lambert@nancy.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Lisa BUHR
Email
l.buhr@nancy.unicancer.fr
Facility Name
Hôpital Edouard Herriot
City
Lyon
State/Province
Rhône
ZIP/Postal Code
69437
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Walter, MD
Email
thomas.walter@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
Melody LAWO
Email
melody.lawo@chu-lyon.fr
Facility Name
Gustave Roussy
City
Villejuif
State/Province
Val De Marne
ZIP/Postal Code
94805
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michel Ducreux, MD, PhD
Phone
+33 (0)1 42 11 60 17
Email
michel.ducreux@gustaveroussy.fr
First Name & Middle Initial & Last Name & Degree
Catherine RICHON
Phone
+33 (0)1 42 11 23 44
Email
catherine.richon@gustaveroussy.fr
Facility Name
Hôpital Croix St Simon
City
Paris
ZIP/Postal Code
75012
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Olivier DUBREUIL, MD
Email
ODubreuil@hopital-dcss.org
First Name & Middle Initial & Last Name & Degree
Amina BOUARICHA
Email
ABouaricha@hopital-dcss.org
Facility Name
Hôpital Saint-Antoine
City
Paris
ZIP/Postal Code
75012
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pauline AFCHAIN, MD
Email
pauline.afchain@aphp.fr
First Name & Middle Initial & Last Name & Degree
Khalida SEGISSEMENT
Email
khalida.segissement-ext@aphp.fr
Facility Name
Hôpital Cochin
City
Paris
ZIP/Postal Code
75014
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Romain CORIAT, MD
Email
romain.coriat@aphp.fr
First Name & Middle Initial & Last Name & Degree
Nadira KADDOUR
Email
nadira.kaddour@aphp.fr
Facility Name
Hôpital Européen Georges Pompidou
City
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Céline FROMONT ép LEPERE, MD
Email
celine.lepere@aphp.fr
First Name & Middle Initial & Last Name & Degree
Fabrice LACAN
Email
fabrice.lacan-ext@aphp.fr
Facility Name
Centre Eugène Marquis
City
Rennes
State/Province
Île-et-Vilaine
ZIP/Postal Code
35000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marc PRACHT, MD
Email
m.pracht@rennes.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Lucile MORVAN
Email
l.morvan@rennes.unicancer.fr

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Two Chemotherapy Regimens Plus or Minus Bevacizumab

We'll reach out to this number within 24 hrs